With the emerging use of real-world data (RWD) and/or synthetic data in clinical trials to support safety and efficacy claims, the European Commission is keenly awaiting the first set of results from half a dozen projects it is funding to harness the use of such data for regulatory decision-making and health technology assessment (HTA).
EU RWE Projects Show The ‘Data Revolution In Health Research' Is Here
The European Commission has invested in several projects on novel real-world evidence methodologies, either via its key funding program for research and innovation or via public-private partnership initiatives.
More from Europe
More from Geography
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
The EU Clinical Trials Information System has achieved primary registry designation in the International Clinical Trials Registry Platform in a move that is expected to reduce regulatory burden for companies and help them lower compliance costs by aligning with publication requirements in medical journals.
• By
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.